Research Disclosures & Disclaimers
This website contains disclosures and disclaimers related topublished UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.
ALX Oncology Holdings Inc (ALXO.O)
UBS Rating and Price Target History Chart
EQ Rating & Price Target Table | ||||||||||||||||||||||||||||||||
|
Disclosures
- UBS Securities LLC makes a market in the securities and/or ADRs of this company.
- Because this security exhibits higher-than-average volatility, the FSR has been set at 25% above the MRA for a Buy rating, and at -25% below the MRA for a Sell rating (compared with 6/-6% under the normal rating system).
- UBS holds a long or short position of 0.5% or more of the listed shares of this company.
Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.
* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.
* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.